Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Terns Pharmaceuticals Inc.

ternspharma.com

Latest From Terns Pharmaceuticals Inc.

Asia Deal Watch: Oxford Biomedica’s First Japanese Partnership Focuses On Rare Retinal Disorder

Oxford Biomedica is teaming with Santen to develop a gene therapy for an undisclosed eye disease. Shionogi inks a pair of partnerships for Chinese rights to lusutrombopag and epertinib.

Deals Asia Pacific

Deal Watch: Gilead Partners With Carna On Small Molecule IO Drug Development

Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.

Business Strategies Commercial

Genfit Assesses Optimal Elafibranor NASH Combo Therapy Opportunity

As it nears the Phase III data readout for elafibranor in NASH, Genfit plans combo therapy studies to determine if a GLP-1 analog or SGLT2 inhibitor would offer the best therapeutic synergy, market potential and partnership opportunity.

Business Strategies Drug Approval Standards

AstraZeneca, Novartis Continued Divestment Sprees In 2018, While Peers Joined The Action

While leading large pharma with seven out-licensing or divestiture deals apiece during 2018, AstraZeneca and Novartis each slowed their pace somewhat. But several peer companies followed suit, as there were 31 such deals among the 20 largest biopharma firms last year.

 

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Hepatic (Liver)
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Terns Pharmaceuticals Inc.
  • Senior Management
  • Weidong Zhong, PhD, Pres. & CEO
    Ankang Li, PhD, CFO
    Erin Quirk, MD, CMO
  • Contact Info
  • Terns Pharmaceuticals Inc.
    Phone: (650) 275-4395
    1065 East Hillsdale
    Ste. 100
    Foster City, CA 94404
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register